Re-emergence of the important role of radionuclide generators to provide diagnostic and therapeutic radionuclides to meet future research and clinical demands

Journal of Radioanalytical and Nuclear Chemistry

Volumn 302, Issue 3, 2014, Pages 1053-1068

  Knapp, F F ^a   Pillai, M R A ^b   Osso, J A ^c   Dash, Ashutosh ^d  

^a OAK RIDGE NATIONAL LABORATORY   (United States)

^b Molecular Group of Companies   (India)

^c INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

^d BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Approved pharmaceutical ingredient (API); Current Good Radiopharmacy Practice (cGRPP); Parent daughter radionuclide; Positron emission tomography (PET); Radiochemical separation; Radionuclide generators

Indexed keywords

ACTINIUM 225; ACTINIUM 227; BISMUTH 213; COPPER 62; GALLIUM 68; GERMANIUM; GERMANIUM 68; INDIUM 113M; MICROSPHERE SN 113; MOLYBDENUM 99; RADIOISOTOPE; RADIUM; RADIUM 223; RHENIUM 188; RUBIDIUM 82; SCANDIUM; SCANDIUM 44; STRONTIUM 82; STRONTIUM 90; TECHNETIUM 99M; TITANIUM; TITANIUM 44; TUNGSTEN; TUNGSTEN 188; UNCLASSIFIED DRUG; YTTRIUM 90; ZINC; ZINC 62;

ARTICLE; AUTOMATION; COLUMN CHROMATOGRAPHY; ISOTOPE LABELING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE VENTRICULOGRAPHY;

EID: 84919422499     PISSN: 02365731     EISSN: 15882780     Source Type: Journal    
DOI: 10.1007/s10967-014-3642-8     Document Type: Article

References (113)

1. Knapp FF Jr, Baum RP (2012) Radionuclide generators—a new renaissance in the development of technologies to provide diagnostic and therapeutic radioisotopes for clinical applications. Curr Radiopharm 6(175–177):2012
2. Lambrecht RM (1983) Radionuclide generators. Radiochim Acta 34:9–24
3. Knapp FF Jr, Mirzadeh S (1994) The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med 21:1151–1165
4. Mirzadeh S, Knapp FF Jr (1996) Biomedical radioisotope generator systems. J Radioanal Nucl Chem 203:471–488
5. Knapp FF Jr, Butler TA (eds) (1984) In: Radionuclide generators: New systems for nuclear medicine applications, ACS Symposium Series 241. American Chemical Society, Washington, DC (USA)
6. Osso J, Knapp FF Jr (2011) In: Theobald T (ed) Sampson’s textbook on radiopharmacy, 4th edn. Pharmaceutical Press, London, pp 339–364
7. Roesch F, Knapp FF Jr (2003) In: Vertes A, Nagy S, Klencsar Z (eds) Handbook of nuclear and radiochemistry. Kluwer Academic Publishers, Amsterdam, pp 81–118
8. Chakravarty R, Dash A (2013) Development of radionuclide generators for biomedical applications. Lambert Academic Publishing GmbH & Co, Saarbrücken
9. Banerjee S, Pillai MRA, Ramamoorthy N (2001) Evolution of Tc-99m in diagnostic radiopharmaceuticals. Sem Nucl Med 31:260–277
10. 99mTechnetium radiopharmaceuticals: manufacture of kits. International Atomic Energy Agency (IAEA), Vienna, Austria. http://www-pub.iaea.org/MTCD/publications/PDF/trs466_web.pdf
11. Eckelman WC (2009) Unparalleled contribution of technetium-99m to medicine over 5 decades. J Am Coll Cardiol Imaging 2:364–368
12. Chakravarty R, Dash A (2014) Nanomaterial based adsorbents: the prospect of developing new generation radionuclide generators to meet future research and clinical demands. J Radioanal Nucl Chem 299(1):741–775
13. 188Re generator and status of current applications. Curr Radiopharm 4(3):228–243
14. 99mTc separation: an assessment of technology options. Nucl Med Biol 40:67–176
15. Chakravarty R, Dash A, Pillai MRA (2012) Electrochemical separation is an attractive strategy for development of radionuclide generators for medical applications. Curr Radiopharm 4:271–287
16. Chakravarty R, Dash A, Pillai MRA (2012) Availability of yttrium-90 from strontium-90: a nuclear medicine perspective. Cancer Biother Radiopharm 27(10):621–641
17. Dash A, Chakravarty R (2014) Electrochemical separation: promises, opportunities, and challenges to develop radionuclide generators of next-generation to meet clinical demands. Ind Eng Chem Res 53(10):3766–3777
18. 188Re generators. IAEA Technical Report Series No. 470, International Atomic Energy Agency (IAEA), Vienna, Austria. http://www-pub.iaea.org/MTCD/publications/PDF/trs470_web.pdf
19. Rösch F, Baum RP (2011) Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to theranostics. Dalton Trans 21(40):6104–6111
20. Rösch F, Baum RP (eds) (2013) Theranostics, gallium-68, and other radionuclides: a pathway to personalized diagnosis and treatment, recent results in cancer research, vol 194. Springer, New York
21. 188W, IAEA Radioisotopes and Radiopharmaceuticals Technical Report Series No. 2, International Atomic Energy Agency (IAEA), Vienna, Austria. http://www-pub.iaea.org/MTCD/publications/PDF/Pub1436_web.pdf
22. Dash A, Knapp FF Jr, Pillai MRA (2013) Industrial radionuclide generators: a potential step towards accelerating radiotracer investigations in industry. RSC Adv 3:14890–14909
23. Pillai MRA, Dash A, Knapp FF Jr (2013) Sustained availability of technetium-99m—possible paths forward. J Nucl Med 54:313–323
24. 113mIn generators. Int J Appl Radiat Isot 20(10):717–724
25. Subramanian G, McAfee JG (1967) A radioisotope generator of indium-113m. Int J Appl Radiat Isot 18:215–221
26. 99mTc. Int J Appl Radiat Isot 28:169–181
27. 112Sn metal. Int J Appl Radiat Isot 33(9):745–749
28. 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Sem Nucl Med 41(4):314–321
29. 68Ga-agents. Appl Radiat Isot 76:14–23
30. Banerjee SR, Pomper MP (2013) Clinical applications of gallium-68. Appl Radiat Isot 76:2–13
31. Decristoforo C (2012) Gallium-68—a new opportunity for PET available from a long shelf life generator—automation and applications. Curr Radiopharm 5:212–220
32. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 39:S52–S60
33. Rice SL, Roney CA, Daumar P, Lewis JS (2011) The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med 41:265–282
34. 68Ga generators: past, present, and future. Rec Res, Cancer Res 194:3–16
35. 68Ga generators. Appl Radiat Isot 76:24–30
36. 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging 34:978–981
37. 68Ga-agents. Appl Radiat Isot 76:14–23
38. 68Ga radiopharmaceutical chemistry. Curr Top Med Chem 10:1633–1668
39. 68Ga-radiopharmaceutical development. Theranostics. 4(1):47–80
40. 68Ga Generator Product Information by Eckert & Ziegler AG, Berlin, Germany. http://www.radiustech.it/public/files/1d000044.pdf
41. 68Ga-labelled peptides for PET imaging of neuroendocrine tumours. Mol Imaging Biol 16(4):550–557
42. 68Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study. Nucl Med Biol 37:149–155
43. 68Ga labeling technique for proteins. J Nucl Med 52:586–591
44. 44Sc radionuclide generator. J Nucl Med 51(Suppl 2):590
45. 44Sc-based PET-radiopharmaceuticals. Radiochimi Acta 98(3):149–156
46. 44Sc generator system. Curr Radiopharm 4(3):187–201
47. 44Sc for clinical application. Appl Radiat Isot 68(9):1636–1641
48. 44gSc production using a water target on a 13 MeV cyclotron. Nucl Med Biol 41(5):401–406
49. 44gSc from natural calcium. Appl Radiat Isot 70(8):1526–1530
50. 44Ti and related reactions. Phys Rev C: Nucl Phys 54(4):2047–2050
51. 44Sc-DOTA-folate conjugate. J Nucl Med 54(12):2168–2174
52. Muller C (2013) Folate-based radiotracers for PET imaging—update and perspective. Molecules 18:5005–5031
53. 44Sc. Appl Radiat Isot 70:974–979
54. 44Sc-DOTA-folate conjugate. J Nucl Med 54:2168–7214
55. Majkowska-Pilip A, Bilewicz A (2011) Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem 105:313–320
56. Mcgee T, Rao CL, Saha GB, Yaffe L (1970) Nuclear interactions of Sc-45 and Zn-68 with protons of medium energy. Nucl Phys A 150:11
57. Sajjad M, Lambrecht RM (1986) Separation of tracer titanium-44 from vanadium. Anal Chem 58:667–668
58. IAEA (2009) Cyclotron produced radionuclides: physical characteristics and production methods. IAEA Technical Report Series 468, International Atomic Energy Agency (IAEA), Vienna, Austria. http://www-pub.iaea.org/MTCD/publications/PubDetails.asp?pubId=7892
59. Robinson GD, F Zielinski FW, Lee AW (1980) The zinc-62/copper-62 generator: a convenient source of copper-62 for radiopharmaceuticals. Int J Radiat Isot 31:111–116
60. Fujibayashi Y, Matsumoto K, Yonekura Y, Konishi J, Yokoyama A (1989) A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. J Nucl Med 30:1838–1842
61. Mathias CJ, Margenau WH, Brodack JW, Welch MJ, Green MA (1991) A remote system for the synthesis of copper-62 labeled Cu(PTSM). Int J Rad Appl Instrum A 42:317–320
62. Dash A, Knapp FF Jr, Pillai MRA (2013) Targeted radionuclide therapy—an overview. Curr Radiopharm 6:152–180
63. Edelman MJ, Clamon G, Kahn D, Magram M, Lister-James J, Line BR (2009) Targeted radiopharmaceutical therapy for advanced lung cancer—Phase I trial of rhenium-188 Re-188 P2045, a somatostatin analog. J Thorac Oncol. 4(12):1550–1554
64. Jeong JM, Knapp FF Jr (2008) Use of the ORNL tungsten-188/rhenium-188 generator for preparation of rhenium-188 HDD/and AHDD/lipiodol complexes for transarterial liver cancer therapy. Semin Nucl Med 38(2):S19–S29
65. Argyrou M, Valassi A, Andreou M, Lyra M (2013) Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy. Int J Mol Imaging 2013:290750. doi:10.1155/2013/290750
66. Knapp FF Jr, Turner JH, Jeong JM, Padhy AK (2004) Issues associated with the use of the tungsten-188/rhenium-188 generator and concentration system and preparation of Re-188-HDD. World J Nucl Med 3:137–143
67. Knapp FF Jr, Beets AL, Guhlke S, Zamora PO, Bender H, Palmedo H, Biersack HJ (1997) Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res 17:1783–1795
68. Callahan AP, Rice DE, Knapp FF Jr (1989) Rhenium-188 for therapeutic applications from an alumina-based tungsten-188/rhenium-188 generator. Nucl. Compact 20:3–6
69. Knapp FF Jr, Lisic EC, Mirzadeh S, Callahan AP (1994) Tungsten-188/carrier-free rhenium-188 perrhenic acid generator system. U.S. Patent No. 5,186,913, Issued 4 Jan 1994
70. 188Re Generators. Appl Radiat Isot 45:1123–1128
71. Abram U, Alberto R (2006) Technetium and rhenium—coordination chemistry and nuclear medical applications. J Braz Chem Soc 17:1486–1500
72. Savio E, Gaudiano J, Robles AM, Balter H, Paolino A, López A, Hermida JC, De Marco E, Martinez G, Osinaga E, Knapp FF Jr (2001) Rhenium-188 HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl Med 1:2–10
73. 188Re(V) DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med 9:1405–1409
74. Liepe K, Hlises R, Kropp J, Gruning T, Runge R, Koch R, Knapp FF Jr, Franke WG (2000) Rhenium-188-HEDP in palliative treatment of bone metastases. Cancer Biother Radiopharm 15:261–265
75. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Grunwald F, Knapp FF Jr, Biersack HJ (2000) Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 27:123–130
76. Knapp FF Jr, Spencer R, Kropp J (2001) Intravascular radiation therapy with radioactive filled balloons for inhibition of restenosis after angioplasty: a new opportunity for nuclear medicine. J Nucl Med 42:1384–1387
77. Weinberger J, Giedd KN, Simon AD, Marboe C, Knapp FF Jr, Trichter F, Amols H (1999) Radioactive beta-emitting solution filled balloon treatment prevents porcine coronary restonosis. Cardiovasc Radiat Med 1:252–256
78. 99mTc complexes of 2-(4′-aminophenyl) benzothiazole as potential breast cancer radiopharmaceuticals. J Med Chem 53:4633–4641
79. 188Re-DTPA-deoxyglucose as a potential cancer radiopharmaceutical. AJR Am J Roentgenol 194(3):761–765
80. 188Re-labeled paper for treating skin cancer. Appl Radiat Isot 58(5):551–555
81. 90Y suitable for targeted therapy. Nucl Med Biol 35:245–252
82. 90Y generator, model KA 01 operating manual. Isotope Technologies Dresden, Germany. http://www.itd-dresden.de/index.php?article_id=78
83. 90Y-labeled RGD peptide dimer in clinically relevant dose. Radiochim Acta 102(6):523–534
84. Dash A, Chakravarty R (2014) Pivotal role of separation chemistry in the development of radionuclide generators to meet clinical demands. RSC Adv 4:42779–42803
85. 90Y for clinical use. Anal Chem 80:801–807
86. 90Y generator systems. J Radioanal Nucl Chem 300(1):355–360
87. 90Y with different bifunctional chelators. Radiochim Acta. doi:10.1515/ract-2013-2190 (in press)
88. 213Bi. Curr Radiopharm 4:295–305
89. Brechbiel MW (2007) Targeted alpha-therapy: past, present, future? Dalton Trans 21:4918–4928
90. Mulford DA, Scheinberg DA, Jurcic JG (2005) The promise of targeted {alpha}-particle therapy. J Nucl Med 46(Suppl 1):199S–204S
91. Kim YS, Brechbiel MW (2012) An overview of targeted alpha therapy. Tumour Biol 33:573–590
92. Vaidyanathan G, Zalutsk MR (1996) Targeted therapy using alpha emitters. Phys Med Biol 41(10):1915–1931
93. Elgqvist J J (2011) Targeted alpha therapy: Part I. Curr Radiopharm 2(4):1–76
94. Morgenstern A, Bruchertseifer F, Apostolidis C (2012) Bismuth-213 and actinium-225—generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Curr Radiopharm 4:221–227
95. Miederer M, Scheinberg DA, McDevitt MR (2008) Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev 60:1371–1382
96. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot 50:895–904
97. 213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Appl Radiat Isot 55:667–678
98. Schwartz J, Jaggi JS, O’Donoghue JA, Ruan S, McDevitt M, Larson SM, Scheinberg DA, Humm JL (2011) Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol 56(3):721–733
99. Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA (2004) Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomicnanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res 10(20):6985–6992
100. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G (2004) Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 10(13):4489–4497
101. Borchardt PE, Yuan RR, Miederer M, McDevitt, Scheinberg DA (2003) Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 63(16):5084–5090
102. Miederer M, Scheinberg DA, McDevitt MR (2008) Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev 60(12):1371–1382
103. Huclier-Markai S, Alliot C, Varmenot N, Cutler CS CS, Barbet J (2012) Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics. Curr Top Med Chem 12:2642–2654
104. Roscher M, Hormann I, Leib O, Marx S, Moreno J, Miltner E, Friesen C (2013) Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 4:218–230
105. Friesen C, Roscher M, Hormann I, Leib O, Marx S, Moreno J, Miltner E (2013) Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur J Cancer 49:2542–2554
106. Kluetz PG, Pierce W, Maher VE, Zhang H, Tang S, Song P, Liu Q, Haber MT, Leutzinger EE, Al-Hakim A, Chen W, Palmby T, Alebachew E, Sridhara R, Ibrahim A, Justice R, Pazdur R (2014) Radium (Ra 223) dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 20(1):9–14
107. Shirley M, McCormack PL (2014) Radium-223 dichloride: a review of Its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs 74(5):579–586
108. Hafeez S, Parker C (2013) Radium-223 for the treatment of prostate cancer. Expert Opin Investig Drugs 22(3):379–387
109. Chiu J-H, Landolt RR, Kessler WV (1978) Separation of rhodium-103 by solvent extraction. Anal Chem 50:670–671
110. Epperson CE, Landolt RR, Kessler WV (1976) Solvent–solvent extraction of rhodium-103m from ruthenium-103 employing a sulfate-carbon tetrachloride medium. Anal Chem 48(7):979–981
111. 103mRh for cancer therapy. J Radioanal Nucl Chem 280(2):371–373
112. 103mRh generator. J Radioanal Nucl Chem 279(2):655–657
113. Boll R, Malkemus D, Mirzadeh S (2005) Production of actinium-225 for alpha particle mediated radioimmunotherapy. App Radiat Isot 62:667–679